Regulus Therapeutics reported $0 in Sales Revenues for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Alnylam Pharmaceuticals ALNY:US $ 187.63M 32.92M
Arena Pharmaceuticals ARNA:US $ 0M 0M
AstraZeneca AZN:LN 9866M 1646M
Astrazeneca AZN:US $ 9866M 1646M
Biogen BIIB:US $ 2778.9M 3.9M
Celldex Therapeutics CLDX:US $ 0.15M 3.33M
Dicerna Pharmaceuticals DRNA:US $ 62.95M 21.62M
Gilead Sciences GILD:US $ 7421M 1204M
GlaxoSmithKline GSK:LN 9077M 985M
Intercept Pharmaceuticals ICPT:US $ 92.83M 3.75M
Intrexon XON:US $ 21.56M 12.02M
Lexicon Pharmaceuticals LXRX:US $ 0.02M 0.21M
Ligand Pharmaceuticals LGND:US $ 64.83M 19.84M
Merk MRK:US $ 13154M 1752M
Omeros OMER:US $ 30M 1.18M
Regulus Therapeutics RGLS:US $ 0M 0M
Sangamo Biosciences SGMO:US $ 28.56M 0.69M
Takeda 4502:JP Y 844820M 104783M
YTE INCY:US $ 812.99M 107.28M